Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Imaging Studies for Cardiovascular System IV: CMRI

Imaging Studies for Cardiovascular System IV: CMRI

Cardiovascular magnetic resonance imaging, or CMRI, is a non-invasive diagnostic test that employs a magnetic field and radiofrequency waves to create precise images of the heart and arteries. It provides comprehensive information about cardiac anatomy, function, perfusion, and tissue characterization without ionizing radiation.IndicationsCMRI diagnoses various heart conditions, including tissue damage from heart attacks, ischemic heart disease, myocarditis, aortic issues (tears, aneurysms,...

Imaging Studies for Cardiovascular System V: CT

Imaging Studies for Cardiovascular System V: CT

Cardiac computed tomography (CT) scanning is an advanced cardiac imaging technique that utilizes CT technology, with or without intravenous (IV) contrast, to produce accurate cross-sectional virtual slices of specific areas of the heart, coronary circulation, and major blood vessels such as the aorta, pulmonary veins, and arteries. The computer processes these slices to generate three-dimensional images. Multidetector CT (MDCT) is a rapid form of CT scanning that captures multiple slices...

Cardiac Catheterization III: Left Heart Catheterization

Cardiac Catheterization III: Left Heart Catheterization

Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

STEMIN- and YAP5SA-induced exosomes prevent cardiomyocyte apoptosis.

iScience·2026

Same author

Distinct populations of vascular smooth muscle and sinoatrial progenitors are localized adjacent to pro-epicardium.

Cell reports·2025

Same author

Tunneling nanotube-like structures regulate distant cellular interactions during heart formation.

Science (New York, N.Y.)·2025

Same author

STEMIN and YAP5SA, the future of heart repair?

Experimental biology and medicine (Maywood, N.J.)·2024

Same author

β1 integrins regulate cellular behaviour and cardiomyocyte organization during ventricular wall formation.

Cardiovascular research·2024

Same author

A Small Molecule That In Vitro Neutralizes Infection of SARS-CoV-2 and Its Most Infectious Variants, Delta, and Omicron.

Biomedicines·2023

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Optical Mapping of Action Potentials and Calcium Transients in the Mouse Heart

Optical Mapping of Action Potentials and Calcium Transients in the Mouse Heart

Published on: September 13, 2011

CAMTA in cardiac hypertrophy.

Robert J Schwartz¹, Michael D Schneider

¹The Institute of Biosciences and Technology, The Texas A&M University System Health Science Center, Houston, TX 77030, USA. rschwartz@ibt.tamhsc.edu

|May 9, 2006

Summary

This summary is machine-generated.

Calmodulin binding transcription activator 2 (CAMTA2) is essential for cardiac hypertrophy. It activates genes involved in this condition by interacting with Nkx2-5 after dissociating from histone deacetylase 5.

More Related Videos

Intra-cardiac Side-Firing Light Catheter for Monitoring Cellular Metabolism using Transmural Absorbance Spectroscopy of Perfused Mammalian Hearts

Intra-cardiac Side-Firing Light Catheter for Monitoring Cellular Metabolism using Transmural Absorbance Spectroscopy of Perfused Mammalian Hearts

Published on: May 12, 2019

A Microscopic 2,3,5-Triphenyltetrazolium Chloride Assay for Accurate and Reliable Analysis of Myocardial Injury

A Microscopic 2,3,5-Triphenyltetrazolium Chloride Assay for Accurate and Reliable Analysis of Myocardial Injury

Published on: November 28, 2025

Related Experiment Videos

Last Updated: Jul 11, 2026

Optical Mapping of Action Potentials and Calcium Transients in the Mouse Heart

Optical Mapping of Action Potentials and Calcium Transients in the Mouse Heart

Published on: September 13, 2011

Intra-cardiac Side-Firing Light Catheter for Monitoring Cellular Metabolism using Transmural Absorbance Spectroscopy of Perfused Mammalian Hearts

Intra-cardiac Side-Firing Light Catheter for Monitoring Cellular Metabolism using Transmural Absorbance Spectroscopy of Perfused Mammalian Hearts

Published on: May 12, 2019

A Microscopic 2,3,5-Triphenyltetrazolium Chloride Assay for Accurate and Reliable Analysis of Myocardial Injury

A Microscopic 2,3,5-Triphenyltetrazolium Chloride Assay for Accurate and Reliable Analysis of Myocardial Injury

Published on: November 28, 2025

Area of Science:

Molecular biology
Cardiovascular research
Gene regulation

Background:

Cardiac hypertrophy is a significant cardiovascular condition.
Understanding the molecular mechanisms driving cardiac hypertrophy is crucial for developing effective treatments.

Purpose of the Study:

To investigate the role of Calmodulin binding transcription activator 2 (CAMTA2) in cardiac hypertrophy.
To elucidate the mechanism by which CAMTA2 regulates genes associated with cardiac hypertrophy.

Main Methods:

The study utilized molecular and genetic techniques to assess CAMTA2 function.
Investigated the interaction between CAMTA2, histone deacetylase 5, and Nkx2-5.

Main Results:

CAMTA2 was identified as an indispensable transcription coactivator for cardiac hypertrophy.
CAMTA2 activation involves the dissociation of class II histone deacetylase 5.
CAMTA2 promotes the transcription of cardiac hypertrophy-related genes via Nkx2-5 interaction.

Conclusions:

CAMTA2 plays a critical role in the development of cardiac hypertrophy.
Targeting the CAMTA2 pathway may offer a therapeutic strategy for cardiac hypertrophy.